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1. Importance 
Glaucoma is the second to macular degeneration as the most common cause of blindness in the 
UK, and worldwide is the leading cause of irreversible blindness. OAG is the most common form 
of glaucoma.1 If OAG is identified early, treatment is effective at reducing progressive disease.2 
The current UK practice of opportunistic case finding, however, misses a majority of cases. Late 
detection is a major risk factor for glaucoma blindness.3 The two main reasons for late detection 
are: 1) poor uptake of community eye care services and 2) inaccurate diagnosis.   
 
Addressing this issue is timely as population screening for OAG is currently under consideration 
by the UK National Screening Committee (UKNSC). Before the introduction of a screening 
programme several criteria need to be met concerning the condition, the test and the screening 
programme.4 Specifically, the UKNSC recommends that direct evidence is required from high 
quality randomised controlled trials (RCTs) that a screening programme is effective in reducing 
mortality or morbidity. 
 
The available literature on the clinical and cost-effectiveness of screening for OAG was 
summarised in a recent health technology assessment (HTA) undertaken by our group.5 No RCTs 
of screening were identified.6 We developed an economic model using parameter estimates 
derived from a series of systematic reviews; this suggested that screening of ‘high risk’ groups 
might be cost-effective, and concluded that a formal targeted RCT was needed. Groups identified 
as having sufficiently high risk of OAG were those with a family history of glaucoma in a first 
degree relative or those of black ethnicity. People with myopia and/or diabetes were also at 
increased risk but, based on the economic modelling, the prevalence might not be sufficient to 
justify a targeted screening programme for them, as they are already examined either through 
the National Diabetic Retinopathy screening programme, or through regular visits to optometrists.  
Considerable uncertainty surrounded the model parameter estimates due to limited primary data 
and further research is required to improve on the model estimates to inform the decisions about 
best practice for screening. A HTA from Finland concluded that in a Finnish context an organised 
screening programme for glaucoma could be a cost-effective strategy, although the model found, 
in contrast to our findings, that screening was more likely to be cost-effective in older age 
groups.7 These differences are most likely explained by differences in model structure and cost 
parameters.  
 
Prompted by these findings and the public health importance of OAG, the international ophthalmic 
community (at specialist society meetings) have called for a trial of screening for OAG versus 
current practice.  
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However, we showed that prior to the conduct of any large definitive screening trial, more robust 
evidence is required to address a number of crucial uncertainties.5 These include: selection of 
optimal screening approaches (including the choice of  screening test); the organisational context 
and which healthcare professionals would administer the test; how best to identify individuals in 
the ‘at risk’ groups e.g. having a  family history is the most significant risk factor in the UK, but 
the most effective and acceptable methods for identifying the index case in the population and 
then identifying relatives is uncertain; and how attendance for screening could be maximised. 
Targeted screening involves issues of ethics, equity, and acceptability to all stakeholders. 
Furthermore, recognition of potential harms and benefits of screening have not been explored in 
a glaucoma context. 
 
Glaucoma is a chronic disease with relatively slow progression requiring long-term monitoring to 
determine effectiveness in terms of reduced incidence of visual impairment. In cancer screening 
RCTs the primary outcome is usually mortality and ascertained from routine data (deaths).  An 
equivalent measure for glaucoma would use routinely collected data on blind and partial sighted 
registration, but such data are currently incomplete and not sufficiently detailed by cause8 to be 
used a trial outcome measure, although efforts are underway to improve this. Therefore, an 
appropriate outcome assessment needs to be determined.  
 
Any outcome assessment should include factors important to the patient. The risks of moderate 
visual loss (the ability to continue to drive) and long-term blindness are reported as the most 
important factors to patients.9 A systematic review of patient reported measures applicable to 
glaucoma (Burr, unpublished results) found that of the existing instruments (generic, vision and 
glaucoma specific) no single instrument appears to have adequate sensitivity, validity, or 
responsiveness for use in its present form as a patient reported outcome (PRO) measure in a 
glaucoma screening trial. Our group have developed a short glaucoma-specific profile instrument, 
which provides a utility score for glaucoma.10 However, the optimal PRO measure(s) for the 
definitive trial needs to comprise items relevant to both disability (e.g. impaired vision; loss of 
driving licence on account of poor vision, and loss of independence) and the screening process 
(capturing benefits such as early detection and treatment and adverse effects such as heightened 
anxiety). 
 
The length of the eventual RCT can be informed by the economic model, based on the most 
efficient screening interval, and the sample size for the trial will be determined by the specific 
group of patients proposed to be screened. The primary outcome will be multidimensional 
(clinical, patient reported and economic). Data on newly detected glaucoma by severity of visual 
field loss, as the primary clinical outcome, are available from clinical records (usually hospital 
based), but whether these are adequately accessible for outcome assessment in the RCT is 
uncertain and exploratory analysis is required. A sensitive PRO measure could conceivably 
capture early patient reported effects, and as such be an appropriate outcome measure.  
 
The aim of this IES platform proposal is to develop the components of the optimal screening 
intervention and outcome assessment to inform the design of the definitive screening trial. In 
addition to providing direct guidance for a definitive RCT, the proposed research is valuable at a 
number of levels as it will inform the broader debate about glaucoma screening; provide insights 
into the configuration of potential future screening programmes; and enhance the relevance to 
patient and consumer needs of future research on screening. 
 
2. Scientific Potential 
2.1 People and track record 
The team brings together all the key disciplines required for successful delivery of this proposed 
IES platform: clinical; ethics; consumer perspective; behaviour change; intervention 
development; economic analysis; trial design; statistical analysis and psychometrics. Applicants 
(Burr, Azuara-Blanco, Garway-Heath, Hernandez, Ramsay, Vale, Viswanathan, 
Wormald) and collaborators (Wright, McPherson) have worked together in recent years on 
glaucoma research including systematic reviews, RCTs, diagnostic studies, economic modelling 
and outcome development.  Burr has published a HTA project on the clinical and cost-
effectiveness of screening for OAG, and developed a preference based measure of health outcome 
for glaucoma.  The applicants include experienced trialists well versed in the design and 
development of complex trials (Campbell, Ramsay, Vale); a chartered health psychologist 
(Francis) specialising in theory-based process evaluations of complex interventions and 
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intervention components relating to behaviour change, and an applied anthropologist (Greene) 
with theoretical expertise in the social and ethical issues around service users’ participation in 
health services, particularly those with chronic illness. Crabb, a reader in statistics and 
measurement in vision, has a particular expertise in methods for detecting visual field progression 
in glaucoma; Wormald, a consultant ophthalmologist with a special interest in glaucoma and co-
ordinating editor of the Cochrane Eyes and Vision group and Professor Roger Hitchings is a 
professor of ophthalmology at Moorfields Eye Hospital and recent president of the European 
Glaucoma Society (EGS).   
 
An Advisory Panel will be convened prior to the start of the study including the co-applicants and 
the named collaborators. These are: Tuulonen, a Professor of Ophthalmology in Finland, author 
of the Finnish Evidence Based Glaucoma guidelines, the Finnish HTA on glaucoma screening and a 
lead in the EGS health economics and glaucoma detection initiatives; Garway-Heath and 
Viswanathan are internationally recognised as experts in glaucoma related research and will 
collaborate in the identification of people with glaucoma staged according to visual field loss for 
validating the PRO measure as well as being members of the advisory panel.  Wright, the Chief 
Executive of the UK-based patient organisation the International Glaucoma Association (IGA); 
McPherson, a community optometrist with experience in glaucoma care, and member of 
Optometry Scotland committee; Bativala represents the Birmingham Research into Glaucoma 
and Ethnicity (ReGAE) group.  A representative from general practice and a consumer will be 
invited representing a glaucoma patient and general user perspective.  The advisory panel will 
meet at the beginning and middle of the project.  Johnston will be a consultant advisor to the 
project contributing senior level experience as a clinical and health psychologist with respect to 
techniques for changing screening behaviours, and theorising and measuring patient reported 
outcomes within the framework of disability.  
 
2.2 Environment 
The project will be led from the Health Services Research Unit (HSRU), and the Health Economics 
Research Unit (HERU), University of Aberdeen. HSRU and HERU are part of the Institute of 
Applied Health Sciences rated 5 in RAE-2001. HSRU provides a critical mass of researchers in a 
range of disciplines across two programmes of work that will inform this research. Specifically 
HSRU has internationally recognised expertise in the design, conduct and analysis, and reporting 
of multi-centre trials in its Health Care Assessment programme, and anthropology, health 
psychology, sociology, and service organisation in its Delivery of Care programme, where the 
emphasis is on research that has potential to inform improvements in the way health care is 
delivered. HERU has a large and successful economic evaluation department.  Both Units have 
long term infrastructure funding in place, making the ideal environment for undertaking any 
definitive screening trial with long term follow up. 
 
2.3 Research plans 
a) Context 
The definitive trial this platform study will inform is a large-scale RCT of a screening intervention 
to reduce glaucoma blindness. This is currently anticipated to be a two armed cluster RCT, 
comparing: 1) targeted glaucoma testing (using standard invitation methods ± enhanced 
invitation [based on behavioural theory to increase uptake]); versus 2) opportunistic case finding 
(current practice). The proposed definitive trial flow is outlined in figure 1, highlighting the areas 
of uncertainty and research questions that need to be answered before a screening trial could 
commence. This proposal addresses each of these questions. 
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b) Research proposed as the platform study 
The proposed research will consist of four stages addressing each research question (see section 
c).  We will adopt a multi-method, multidisciplinary approach involving social anthropology, 
health psychology, health economics, statistics and clinical epidemiology to address these 
questions. The findings of each stage will be used to refine our existing economic model that in 
turn will inform the final trial design. 
 
c)  Research methodology/analysis proposed 
Research Question Q1: What screening strategy (i.e., test; site; target population; 
provider) will give the optimal combination of feasibility and acceptability to providers?  
(Months 1-12) 
Q1a) Aim: To determine the optimal screening strategy (test[s], site, target population and 
provider). Screening tests for glaucoma include measures of structure (looking at the degree of 
optic nerve damage by imaging) and function (visual field loss) and intraocular pressure (IOP). 
There are many screening tests and combinations of tests that could be used in a screening 
programme; these were identified and evaluated in our recent report.5 Some performed poorly, 
but those remaining all performed reasonably well for diagnostic accuracy. No single test or 
combination of tests was clearly superior. Selection of an optimal test or test combination 
therefore rests on the feasibility and acceptability to both users and service providers. A matrix of 
test accuracy, portability, and proportion of users able to undertake the test, ‘at risk’ population 
and options for screening sites will be developed based on our previous report.5 Using this matrix, 
potential tests, the target population and testing arrangements will be short listed by consensus 
with expert clinicians and users at the first Project Advisory meeting. 
 
Q1b) Aim: To determine the feasibility and acceptability of these screening strategies in a service 
context. Although potential screening strategies can be identified, it is important to assess health 
professionals’ views about whether these could be implemented in practice before they are 
formally accepted as a screening intervention for inclusion in the definitive trial. We will assess 
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the barriers and facilitators to the introduction of the short listed test strategies through a formal 
exploration of the context in which such screening techniques could be applied. We will use 
established methods in social anthropology to tap multiple perspectives to gain an understanding 
of the issues that impact on the design and implementation of eye care services from the 
perspectives of key stakeholders (health professionals and policy makers). 
 
We will collaborate with VISION 2020 UK (an umbrella organisation which facilitates greater 
collaboration and co-operation between organisations within the UK which focus on visual 
impairment), the relevant Royal Colleges, representatives from the UKNSC and the National 
Diabetic Retinopathy Screening Programme to identify, and facilitate recruitment, of key 
personnel from primary and secondary care, and policy makers across the UK. Interviewees will 
be purposively sampled from this sampling frame to examine variations and perceptions of 
current testing practices and the potential impact of screening on clinical and process of care 
outcomes, interdisciplinary working and resource needs. Health care professionals will include 
GPs, nurse practitioners, and optometrists (n=10+10+10) and secondary care professionals 
[ophthalmologists] (n=10). Policy makers will include chief executives of primary and secondary 
care trusts, Directors of Public Health and a representative from VISION2020 and a 
representative from the UKNSC (n= 5).  Semi-structured interview protocols will be designed to 
address the key research questions and qualitative issues summarised in Boxes 1 & 2, whilst 
maintaining sufficient flexibility to accommodate respondents’ novel ideas. The protocols will be 
informed by the clinical expertise on the Project Advisory Panel, and policy document review e.g. 
current planned reconfigurations of eye care services in the UK.11-13 Interviews with policy makers 
will address historical, practical and strategic issues as well as reflections on potential for changes 
in practice. Interviews with clinical staff will focus more closely on perceptions of screening and 
implications for practice. Interviews will be conducted mainly by telephone and will last no more 
than an hour. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anthropological field notes will be taken during and immediately after each interview, interviews 
will be recorded to enable field note validation (both internal and external validation by getting 
20% of interview summaries independently analysed). Two forms of analysis will be presented:  
holistic anthropological summaries and qualitative content analysis of key themes and issues by 
stakeholder type. It is likely that the analysis of interviews with health professionals and policy 
makers will reveal matches and mismatches in perspectives between these different stakeholders. 
These matches and mismatches will be explored in focus group discussions with optometrists 
BOX 1.  Current context of glaucoma detection 
•  History & context To determine the current strategy of testing; how has this evolved? 
Who are the key players? What are the lines of responsibility/accountability?  
• Organisational structure To determine what screening / identification strategies (i.e. test; 
site; provider; population) will be the most feasible and acceptable to providers in the UK?  
• Managing change: What changes to ways of working are anticipated? What are the 
expected drivers and barriers to change / implementation? 
• Multidisciplinary networking: How successful is interdisciplinary working across 
boundaries in the screening context? Perceived obstacles? 
•  Measuring quality and benefits: What are the expected benefits for health professionals 
and policy makers of a screening intervention (i.e. quality assurance and audit)?  
BOX 2.  Perspectives on glaucoma screening  
• What is understood by OAG screening, i.e., its importance, training required and the service 
provided?  
• What are the issues relating to the ethics and equity of targeting subgroups?  Is it 
acceptable to consider selective screening? Which groups are perceived to be most at risk? 
How should they be approached?  
• What are perceived to have been the major barriers and facilitators to glaucoma detection, 
e.g., how to test; motivate user attendance; service issues around test positives?  
• What role do the different stakeholders play in supporting screening implementation?  
• What are the actual and potential benefits and drawbacks of screening as perceived by staff 
in these practices and specialities? 
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(max n=6 in group) and ophthalmologists (max n=6 in group) in which similar topics are covered 
and areas of controversy and dissent within the group specifically explored.14 The outputs of 
these discussions will indicate the two most appropriate and feasible configurations of the target 
population and screening intervention to inform the investigation of research questions 2&3 and 
clarify any issues in implementation that may need extra care.   
 
Research Question Q2:  How feasible are the proposed identification strategies for 
individuals in each at-risk group, and given the results what is the most appropriate 
unit of clustering?  (Months 13-24) 
Aim: To determine the target group(s) for screening, and inform the unit of clustering for the 
definitive trial. Having identified two possible testing strategies, we will explore the feasibility of 
identifying the population on whom screening is felt to be appropriate and acceptable. The 
feasibility of identifying the target population from routine data sources will be explored, tested 
and reported. Identification methods are likely to differ for the different risk groups: e.g. family 
history (relatives of patients with glaucoma diagnosis – primary care/secondary care records); 
black ethnicity (community groups); myopia (optometry records); diabetes (diabetes registers). 
Issues such as accessibility, coverage and accuracy will be recorded.  We will also test the 
feasibility of identifying individuals selected on age alone through primary care databases or using 
a brief questionnaire asking people to self-identify if they are in one of the specified risk groups. 
We will work with other relevant groups, including the National Diabetic Retinopathy Screening 
Programme, other research groups developing strategies to improve case detection for siblings of 
people with diagnosed OAG,15-17 the Centre for Research in Ethnic Relations (CRER) based at the 
University of Warwick and the ReGAE group who are exploring attitudes and beliefs, in an Afro-
Caribbean population, related to eye disease18-20 to build on their collective experience on the 
feasibility of accessing ‘high-risk’ groups. 
 
The outcome of this phase of the research will be judged in terms of the feasibility (is it possible) 
and time (cost) to identify the target population. This will be compared with cost of recruiting the 
general population, i.e. based on age alone. These data will then be incorporated into the 
economic model, along with information from Q3b below, to determine whether inviting high-risk 
individuals remains a viable intervention.  
 
Research question Q3: What are the most likely effective interventions for maximising 
attendance by the target individuals? (Months 9-24) 
Q3a) Aim: To identify relevant beliefs and uptake intentions, to inform a theory based 
questionnaire. Semi-structured interviews will be conducted with people in the defined target 
population to elicit their views about attending for a screening test. Description of the screening 
test and the configuration of the screening test and the target population will be decided on the 
basis of data from Q1. Interview protocols will be theory-based and will employ the methods used 
by the research team (MJ, MC, JF) in a current MRC-funded project on acceptability of genetic 
testing for Paget’s disease.21 Participants will be identified from primary care records, patient and 
community organisations including the International Glaucoma Association [IGA], the Royal 
National Institute for Blind people [RNIB], the ReGAE group and volunteers recruited by notices in 
optometry and glaucoma clinics advertising the study. The sample (n = 20, or more if needed to 
achieve data saturation) will be purposively sampled to represent a range of demographic 
characteristics and levels of risk for glaucoma. Data from these elicitation interviews will be used 
to generate questionnaire items (for Q3b), thereby ensuring that these items have high relevance 
for these groups. In addition, people (n = 10) who were diagnosed at a late stage, i.e. severe 
glaucoma, will be interviewed and asked to reflect on when and why they did or did not attend for 
glaucoma testing; how their condition was detected (e.g. through testing or noticeable 
symptoms, or whether they were tested and not detected); and at what stage they felt their 
Quality of Life (QoL) was affected (in terms of Activity limitations and Participation restrictions – 
see Q4b). These will give rise to further questionnaire items if appropriate. 
 
Q3b) Aim: To identify predictors of intentions to attend for glaucoma screening. 
Screening uptake requires that individuals, first, decide to attend for screening and second, 
actually attend at the screening location. That is, uptake involves intentional behaviour. Predictive 
models of intention and behaviour from psychology make the assumption that how people think 
will influence what they do. Three types of such beliefs and attitudes (whether a person thinks 
the advantages of attending for screening outweigh the disadvantages); subjective norms 
(whether a person thinks that other people would approve or disapprove of them attending for 
 7 
screening); and perceived control over doing the behaviour (whether a person thinks that it is 
easy or difficult and whether there are barriers or facilitators to attending screening). The types 
of beliefs assessed will be informed by the theoretical model, the Theory of Planned Behaviour,22 
and the content of the questionnaire items will be determined by the interview data (from Q3a) in 
accordance with standard practice in the field.23  The questionnaire will be sent to 200 individuals 
in each high-risk group and 200 in the general population using the same sampling frame 
described in Q3a. This sample size will have 80% power to detect a difference of 0.33 SD in 
intention scores between the general population and targeted groups.  The theoretical constructs 
that predict intention to attend for testing will be identified from questionnaire data using a 
multiple regression approach. These predictors will be mapped on to select behaviour change 
techniques most likely to maximise uptake of testing.24 In addition, the specific beliefs that 
discriminate between high intenders and low intenders will be identified using t-tests. These 
‘discriminant beliefs’ will also inform the content of the intervention. 
 
Our group (MJ, JF and colleagues) are refining the methods for identifying components of 
behaviour change interventions most likely to be effective in this context, covering two aspects of 
change: motivation and action. We will use these methods together with the questionnaire data 
to specify a behaviour change intervention to maximise screening uptake. 
 
Research Question Q4:  What are the most appropriate methods for obtaining primary 
clinical and patient reported outcomes for use in the trial? (Months 1-24) 
Q4a) Aim: To determine the feasibility of ascertaining clinical outcome from patient records and 
routine data. The primary clinical outcome of the definitive RCT will be newly detected glaucoma, 
detailed by severity, with blindness as the long-term outcome. We will explore the feasibility and 
completeness of ascertainment of newly detected glaucoma from UK hospital clinic records. In 
particular we will determine the coverage of an electronic patient record for glaucoma since this 
would be the preferred mode of primary outcome assessment in the definitive trial. Feasibility will 
be determined in terms of availability, and possibility of developing a trial-specific electronic data 
capture mechanism for the definitive RCT. We will also examine the feasibility and completeness 
of flagging for glaucoma events through Hospital Episode Statistics (HES) data in England; 
Information Statistics Division (ISD) data in Scotland; and registration of visual impairment.   
 
Q4b) Aim: To develop and test the patient reported outcome (PRO) measure (content, and 
validity). Building on our existing work, and our systematic review of PRO measures used in 
glaucoma, we will systematically identify PRO instruments used in screening or public health 
intervention studies in other disease areas. Based on these (and our already identified item bank 
from glaucoma specific measures) potential items (questions) to be included in the PRO to be 
used in the trial will be determined by a rigorous theoretical approach by mapping each of the 
items on to the constructs in the WHO model of disability: Impairment (I); Activity limitations 
(A); and Participation restrictions (P). Using the process of Discriminant Content Validation 
(developed by MJ and colleagues;25) the ‘pure’ items for each of these constructs will be identified 
so that relationships between the constructs can validly be explored and a greater understanding 
of the PRO measure can be achieved. This approach is particularly important for a glaucoma 
screening RCT as it could distinguish between the QoL effects associated with screening and those 
associated with vision-related activity limitation and participation restriction. The PRO will be 
evaluated in the target population (500 participants) identified from three sites (Aberdeen, 
Birmingham, London [Moorfields Eye Hospital]) including people with OAG (mild, moderate and 
severe defined on the basis of binocular visual field loss – 125 people in each category) and those 
without glaucoma (125 people).  The evaluation will use exploratory factor analysis to identify 
components, test convergent validity with other related QoL measures and test discriminant 
validity across the different categories of people. We will also explore any differences obtained 
with a Rasch Item Response Theory approach. The sample size of 500 was estimated using the 
recognised rule of thumb that approximately 20 observations per item in the exploratory factor 
analysis are required to estimate a valid model.26 This allows a maximum of 25 items to be used 
in the exploratory model.  
 
Health Economics: Research questions 1-4 (Months 1-24) 
Aim: To refine the existing economic model providing an updated estimate of the cost-
effectiveness of alternative screening strategies. One criterion for adoption of screening for OAG 
will be its cost-effectiveness compared with other relevant strategies.  Our proposed RCT will 
include an economic evaluation, it is important that the included strategies are relevant to the 
 8 
NHS.  The development of these strategies can be informed by a model based economic 
evaluation, as this model can test the likelihood that different hypothetical strategies might be 
cost-effective.  If some strategies appear potentially cost-effective for a range of feasible values 
for key model parameters, then, it is likely that these strategies will also be potentially cost-
effective within a trial based economic evaluation.   
 
New information generated within this project will be incorporated into the existing model and 
where necessary this model will be refined to reflect the new insights gained.  Each stage of the 
research will suggest potential alternative ways in which a screening strategy will be organised.  
As these new ways are developed they will be considered by the economic modelling exercise and 
those ways that seem most likely to be cost-effective identified. This information will be fed back 
to the research team so that the research can be focused on those potential ways of organising a 
screening strategy that appear most promising.  For instance, information from research question 
Q1a, on potentially acceptable screening strategies, will be used to define a set of screening 
strategies within the economic model; subsequently, the economic model can be used to assess 
the expected effectiveness and efficiency of those strategies. These will be presented to the 
stakeholders (Q1b) and feasibility discussed. Therefore, the economic analyses will be used in an 
iterative manner alongside other stages throughout this project in order to refine hypotheses and 
research objectives in subsequent stages. 
 
The economic model will incorporate all new data available on costs, probabilities and health 
outcomes (e.g. Quality Adjusted Life Years –QALYs-). Model results will be obtained in terms of 
cost per QALY but also in terms of clinical and natural outcomes e.g. number of cases detected. 
Model uncertainty will be explored with sensitivity analyses. This is likely to involve deterministic 
and probabilistic sensitivity analyses. Cost effectiveness acceptability curves are expected to be 
used to present results.  A final element of the modelling exercise will be to explore the value of 
information of the screening strategies considered most relevant for inclusion in the screening 
RCT.  The purpose of this exercise will be to identify the most important areas for data collection 
within the trial.   
 
Key deliverables of the proposed research. 
By optimising both the screening strategy and the intervention to maximise uptake, and by 
defining the outcome schedule, this research will enable a precise and evidence-based trial 
protocol to be developed that has the best opportunity to demonstrate the success or not of a 
glaucoma screening programme.  Specific deliverables from the research will thus include: 
1. Acceptable screening strategy (test, site, and target population); 
2. Feasible strategies to invite individuals in each of the target groups; 
3. Informed trial design (unit of clustering); 
4. A decision as to whether a behavioural intervention might increase uptake of screening; 
5. An updated economic model to inform the RCT and to which data from an RCT can 
subsequently contribute; 
6. Defined trial outcomes.  
 
Decision rules for progression to definitive trial 
The IES platform will be considered successful if a feasible and acceptable intervention can be 
identified to take to full trial and if primary clinical and patient reported outcomes can be feasibly 
collected. Questionable feasibility may include a significant minority of a stakeholder group 
finding any proposed screening intervention unacceptable.   
 
4) Ethics and research governance. 
We believe the proposed research does not pose any specific risks to individual participants nor 
does it raise any extraordinary ethical issues.  We will submit our research proposal for review 
and approval to the appropriate Research Ethics Committees via the National Research Ethics 
Service and to any relevant NHS Research and Development committees.  We will abide by the 
MRC’s guidelines on Good Research Practice and follow the University of Aberdeen’s Research 
Governance guidelines.  In addition we will convene a project advisory group to monitor and 
review the progress of the study. 
 
5) Data preservation for sharing.   
The applicants will comply with the MRC policy on data sharing and preservation and agree that 
valuable data arising from this research will be made available to the scientific community with as 
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few restrictions as possible and shared in a timely and responsible manner.  All consent forms will 
state that other researchers may wish to access (anonymised) data in the future. Burr as the 
Chief Investigator will ensure compliance with legal, data protection and ethical guidelines. 
 
6) Public engagement in Science 
Involving patients and the public is an important component of decisions regarding a population 
screening intervention. This research proposal involves potential users and patient organisations 
throughout. We have worked with the International Glaucoma Association (IGA) on our previous 
projects in the area.5,10 David Wright, the Chief Executive of the IGA has agreed, on behalf of the 
IGA, to collaborate. We will involve two consumers in our Advisory Panel, a glaucoma patient 
representative and we will seek another consumer identified from a patient organisation or 
community association.  
 
7) Exploitation and dissemination. 
The results if the study will be disseminated in several ways: 
1) A final grant report to the MRC; 2) A series of open access publications detailing the results if 
the study; 3) An updated report to the UK National Screening Committee; 4) Presentations to 
relevant health care professional and policy audience; 5) lay summaries of main findings for 
relevant patient organisations and communities, and ultimately to lead and eventually provide 
evidence from a multi-centre trial of the effectiveness of an intervention to improve case health 
outcomes for those at risk of losing vision from OAG. 
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